CSTL — Castle Biosciences, Inc.

Castle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $83.7 million for Q1 2026, a significant increase driven by core revenue drivers.
• Test Volume Growth: Core revenue drivers saw a 36% increase in test report volumes year-over-year. Excluding DecisionDx-SCC and ID Genetics, revenue growth was approximately 42%.
• Gross Margin: 72.8%, up from 49.2% in Q1 2025 (notably impacted by a one-time amortization expense in 2025).
• Adjusted Gross Margin: 75.6%, down from 81.2% in Q1 2025.
• Net Loss: $14.5 million, improved from a loss of $25.8 million in Q1 2025.
• Diluted Loss Per Share: $0.49, compared to $0.90 in the prior year.
• Adjusted EBITDA: Negative $5.1 million, an improvement from negative $13.0 million in Q1 2025.
• Cash Position: $261.7 million in cash, cash equivalents, and marketable securities as of March 31, 2026.

2. Strategic Updates and Business Highlights

• Core Revenue Drivers:
  • DecisionDx-Melanoma: 10,021 test reports in Q1, 16% growth year-over-year. March 2026 was a record month for test reports.
  • TissueCypher: 11,745 test reports, representing 58% growth year-over-year, with March also being a record month.
• Advanced ADTx Test: Received approximately 650 orders in Q1 2026, with positive clinician feedback. The company plans to provide reimbursement updates by the end of Q3 2026.
• M&A Strategy: The company remains open to evaluating M&A opportunities that align with its strategic goals.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised for 2026 to a range of $345 million to $355 million, up from $340 million to $350 million.
• Volume Growth Expectations: Mid to high single-digit growth anticipated for DecisionDx-Melanoma for the full year, with expectations for TissueCypher to maintain a similar growth trajectory as in 2025.

4. Bad News, Challenges, or Points of Concern

• Sequential Decline in TissueCypher Volume: Although year-over-year growth was strong, there was a modest quarter-over-quarter decline attributed to seasonal factors, which had not been observed since early 2024.
• Operating Expenses: Total operating expenses were $102.1 million, with increases in sales and marketing expenses driven by personnel costs and travel expenses.
• Cash Flow Concerns: Net cash used in operating activities was $22.1 million, raising questions about the path to cash flow positivity, which has been a stated goal for 2026-2027.

5. Notable Q&A Insights

• TissueCypher Volume Dynamics: Management acknowledged the impact of seasonality on test volumes and indicated that March and April showed strong performance, suggesting a potential rebound.
• Reimbursement for Advanced ADTx: Management expects to provide clarity on reimbursement processes by Q3 2026, focusing primarily on traditional payer categories.
• Feedback on NCCN Guidelines: Clinicians expressed confusion regarding NCCN's stance, suggesting that the guidelines may be influenced by external factors rather than clinical data.
• M&A Considerations: Management emphasized a cautious approach to M&A, indicating they are not compelled to pursue acquisitions but remain open to opportunities that align with their strategic vision.

This summary encapsulates the key points from Castle Biosciences' Q1 2026 earnings call, highlighting both the positive momentum and the challenges faced by the company.